Motexafin gadolinium

Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.[1]

Motexafin gadolinium

Clinical data
ATC code	none
Identifiers
CAS Number	156436-89-4^Y
PubChem CID	158385
ChemSpider	139341^Y
UNII	6433A42F4F
KEGG	D05080^Y
ChEBI	CHEBI:50161^Y
CompTox Dashboard (EPA)	DTXSID4037083
Chemical and physical data
Formula	C52H72GdN5O14
Molar mass	1148.42 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].[Gd+3]
InChI InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2/b39-27-,40-28-,41-27-,42-28-,45-31-,46-32-,49-31+,49-43+,50-32+,50-44+;;;^Y Key:VAZLWPAHMORDGR-WRIGXHCHSA-L^Y
(verify)

History

On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]

On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]

References

1. Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert Opinion on Pharmacotherapy. 8 (3): 351–9. doi:10.1517/14656566.8.3.351. PMID 17266469.
2. Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
3. Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases